New research suggests a path forward that could change the lives of millions who are losing vision due to retinal damage and ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will highlight its pioneering modifier gene therapy platform at two major industry ...

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD CHENGDU, China and ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- Chengdu Origen ...

Blocking the PROX1 protein allowed KAIST researchers to regenerate damaged retinas and restore vision in mice. Vision is one ...

“We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the ...

Researchers evaluate key measures for tracking disease progression in Usher syndrome type 2–related retinal degeneration ...

Retina: Gene Therapy and Novel Mechanisms of Action – Dr. Jared Stephens, Vice President, Strategy and Business Development ...

Many diseases are caused by a missing or defective copy of a single gene. For decades, scientists have been working on gene ...